NDRA · ENDRA Life Sciences Inc
United States · RS rating 57 · As of 2026-11-03
| Price | 4.86 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 57 / 19 / 79 / 45 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 28 / 28 / 43 |
| Industry group (rank) | Medical-Systems/Equip (86) |
| EPS growth Q/Q | +105.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +27.5% |
| Market cap (USD) | $6.2M |